Elanco Animal Health (NYSE:ELAN) Posts Quarterly Earnings Results, Misses Estimates By $0.01 EPS

Elanco Animal Health (NYSE:ELAN) issued its quarterly earnings data on Tuesday. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01), Zacks reports. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share.

Elanco Animal Health Stock Down 5.4 %

NYSE ELAN opened at $10.51 on Tuesday. Elanco Animal Health has a 52 week low of $10.65 and a 52 week high of $18.80. The firm has a market capitalization of $5.20 billion, a price-to-earnings ratio of 26.26, a PEG ratio of 2.50 and a beta of 1.42. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. The company has a fifty day moving average of $11.78 and a two-hundred day moving average of $13.09.

Analysts Set New Price Targets

Several equities research analysts recently commented on ELAN shares. Barclays lifted their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, November 8th. Morgan Stanley cut their price target on Elanco Animal Health from $15.00 to $14.00 and set an “equal weight” rating for the company in a report on Wednesday, January 29th. Stifel Nicolaus reduced their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating for the company in a research note on Friday. Leerink Partnrs raised Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Finally, UBS Group assumed coverage on Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $16.00.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.